IZERVAY dosing approved beyond 12 monthsTOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Ok ...

Exelixis has made significant strides in establishing itself as a multi-compound, multi-franchise oncology business.

Scotiabank analyst Greg Harrison raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $27 and keeps an Outperform rating ...

Scotiabank (TSX:BNS) analyst Greg Harrison increased the price target on Travere Therapeutics (NASDAQ:TVTX) to $32.00, up from the previous $27.00, while retaining a Sector Outperform rating for the ...

Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

Exelixis Inc (EXEL) reports robust financial performance and outlines ambitious goals for its oncology portfolio amid market ...

CEO Mike Morrissey highlighted significant momentum in 2024, emphasizing the company's goal of achieving $3 billion in annual cabozantinib (Cabo) revenue by 2030 and $5 billion for zanzalintinib ...

Travere Therapeutics aims to seek traditional approval based on data from the Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI, with submission expected by the end of the first quarter of 2025. The ...

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) rose 7% following the company's announcement of its intent to submit a ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ...